Evidence map›Paper›PMID 15681856›Full record

ReviewEndocrine pathology2004

Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas.

Yuri E Nikiforov

Abstract readReview
PubMed Publisher
In one paragraph

Review in Endocrine pathology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 234 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Deiodinases in thyroid tumorigenesis.Endocrine-related cancer · 2023
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Yuri E NikiforovDepartment of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, OH 45267-0529, USA. Yuri.Nikiforov@uc.edu
University of Cincinnati Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent molecular studies have provided new insights into thyroid carcinogenesis. In thyroid papillary carcinomas at least three initiating events may occur, which are point mutations in the BRAF and RAS genes and RET/PTC rearrangements. Tumors harboring mutant BRAF and RAS are prone to progression to poorly differentiated and anaplastic carcinoma, but most likely require additional mutations to trigger this process. In thyroid follicular carcinomas, two known initiating events are RAS mutations and PAX8-PPARgamma rearrangements, and RAS predisposes to dedifferentiation of follicular carcinomas. p53 and beta-catenin mutations, found with increasing incidence in poorly differentiated and anaplastic carcinomas but not in well-differentiated tumors, may serve as a direct molecular trigger of tumor dedifferentiation. Additional evidence for progression from a preexisting well-differentiated carcinoma to poorly differentiated and anaplastic carcinoma comes from the studies of loss of heterozygosity and comparative genomic hybridization. Molecular studies, although limited by the lack of uniform histologic criteria for poorly differentiated carcinomas, revealed no genetic mutations or chromosomal abnormalities that are unique for poorly differentiated carcinoma and not present in well-differentiated or anaplastic carcinomas. This suggests that poorly differentiated carcinoma, as a group, represents a distinct step in the evolution from well-differentiated to anaplastic thyroid carcinoma, rather than an entirely separate type of thyroid malignancy.

Indexed as

Point MutationAdenocarcinoma, FollicularAdenocarcinoma, PapillaryCarcinomaCell Transformation, NeoplasticDNA-Binding ProteinsGenes, p53Genes, rasNuclear ProteinsOncogene ProteinsOncogene Proteins, FusionPPAR gammaProtein-Tyrosine KinasesProto-Oncogene Proteins B-rafThyroid NeoplasmsTrans-ActivatorsBRAF protein, humanDNA-Binding ProteinsNuclear ProteinsOncogene ProteinsOncogene Proteins, FusionPPAR gammaProtein-Tyrosine KinasesProto-Oncogene Proteins B-rafret-PTC fusion oncoproteins, humanTrans-Activators

Identifiers

PMID15681856
OpenAlexW2022708037

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.